Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 28    symbols : RETA    save search
Reata Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Bardoxolone Methyl in Chronic Kidney Disease Caused by Alport Syndrome
Published: 2021-10-28 (Crawled : 21:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0 twitter stocktwits trandingview |
Health Technology
 | | O: 0.23% H: 3.98% C: 0.03%
disease europe application kidney syndros
Gainers vs Losers
67% 33%

Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.